Clinical Research Directory

Inclusion Criteria: 1. Patient must have signed an Institutional Review Board (IRB) approved informed consent document indicating that they understand the purpose of and procedures required by the study and are willing to participate in the study and comply with all study procedures and restrictions. Informed consent must be obtained from the patient and/or a designated representative prior to initiating screening procedures to evaluate eligibility of the study. 2. Males and females aged 40 - 80 years inclusive. 3. Meet criteria for the diagnosis of possible/ probable idiopathic Parkinson's disease (PD; Postuma RB, et al. 2015) 4. Have not previously been treated with CD/LD. 5. PD severity in the Hoehn \& Yahr 2 to 3 range. Exclusion Criteria: 1. Women who are pregnant or may become pregnant. 2. Nursing mothers. 3. Individuals who have taken a study medication (pramipexole and/or aprepitant) within 3 months of study admission. 4. Moderate and severe renal impairment (Creatinine Clearance: \< 60 mL/min calculated by Cockcroft and Gault equation) 5. Severe hepatic impairment (Child-Pugh C) 6. Hypersensitivity to any component of either study medication 7. Being treated with the following medications: * Pramipexole * Centrally acting dopamine antagonists during preceding month * Pimozide * Strong CYP3A4 inducer or inhibitor * Warfarin (a CYP2C9 substrate) * Hormonal contraceptives 8. Patients considered unlikely to co-operate in the study, and/or poor compliance anticipated by the investigator. 9. Patients who have any clinically significant hypotension or ECG abnormality. 10. Any other clinically relevant acute or chronic diseases which could interfere with patients' safety during the trial, or expose them to undue risk, or which could interfere with study objectives. 11. Patients who have participated in another clinical trial with an investigational drug within previous 30 days.